

SENSIPAR (cinacalcet)

Diagnoses Considered for Coverage:

- Hypercalcemia with primary hyperparathyroidism
- Secondary hyperparathyroidism associated with chronic kidney disease
- Hypercalcemia with parathyroid carcinoma

Coverage Criteria:

1. For diagnosis of hypercalcemia with primary hyperparathyroidism:

- Diagnosis was confirmed by an Endocrinologist, and
- One of the following:
 - Patient is currently experiencing hypercalcemia despite parathyroidectomy, or
 - Patient is unable to undergo parathyroidectomy and
- Dose does not exceed 360 mg per day

2. <u>For diagnosis of secondary hyperparathyroidism associated with chronic kidney</u> disease:

- Patient has chronic kidney disease that requires dialysis, and
- Inadequate response or intolerable side effect to one standard therapy (vitamin D analog, sevelamer, calcium acetate) OR contraindication to all standard therapies.
- Dose does not exceed 300mg per day

3. For diagnosis of hypercalcemia in a patient with parathyroid carcinoma.

• Dose does not exceed 360mg per day

Coverage Duration: one year

Effective Date: 11/29/2023